Compare DexCom, Inc. (DXCM) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Roundhill NVDA WeeklyPay ETF trades at $37.11 (market cap $119.10M). The key difference: DexCom, Inc. is far larger — about 267.5× Roundhill NVDA WeeklyPay ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Roundhill NVDA WeeklyPay ETF for 50 Days on average.
| DXCM | NVDW | |
|---|---|---|
Market Cap | $31.86B | $119.10M |
Volume | 3,607,070 | 44,838 |
Sector | Health | Income / Options Overlay |
52-Week High | $92.34 | $52.33 |
52-Week Low | $54.84 | $31.88 |
Typical Hold Time | 62 Days | 50 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
NVDW trades at $37.11, down 4.11% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF provides weekly dividend income tied to Nvidia's performance with 120% leveraged exposure. Recent Nvidia earnings beat expectations, supporting the AI theme's momentum, though the fund carries elevated risk due to leverage and NAV volatility during Nvidia downturns.
The outlook remains tied to Nvidia's AI-driven growth, offering high-yield income potential but with significant volatility risk. Investors face exposure to Nvidia's stock performance amplified by leverage, making the fund suitable for risk-tolerant income seekers but vulnerable to sharp corrections in the underlying asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
